Torrent PharmaceuticalsQ1 FY24

Torrent Pharmaceuticals Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹4,668.8P/E: 81.8Market Cap: ₹1.8L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • India business expected to outperform market with single-digit growth overall and double-digit growth ex-Curatio, driven by chronic and new product segments.
  • Curatio portfolio shows 18% growth with further margin expansion expected; base business margins targeted in near future.
  • Brazil business projects healthy double-digit growth (~15%) supported by new product launches and rep additions; Q3-Q4 stronger seasonally.
  • Germany business recovery anticipated with new tender wins boosting sales from Q4 onwards.
  • US business to maintain niche, profitable presence with gradual growth expected from new product approvals, aiming for $50-60 million quarterly sales in 2-3 years.
  • Volume growth in India internal trends positive with 1-2% higher than market volume growth expected.
  • Margin improvements of 75-100 basis points per year expected driven by price increases and operating leverage.
  • Consumer health business to add 3-5 products over 1-2 years, with fixed costs largely absorbed already.

See what Torrent Pharmaceuticals management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • No specific mention of current or planned new fundraising through debt or equity on page 15 or the surrounding pages.
  • The company stated they do not see a need for expansion in the MR (medical representative) force currently, implying no immediate major capital raise for sales expansion.
  • Net debt to EBITDA as of June 30 is 1.3x, with plans to repay another Rs. 600 crores during the year, indicating focus on debt reduction rather than new debt raising.
  • Capital allocation priorities remain on internal growth and investment primarily in branded generics markets rather than aggressive external fundraising.
  • The US business is not a primary focus area for large capital investments at this time.
  • Overall, no indications of imminent debt or equity fundraising; focus is on judicious capital use and debt repayment.

See what Torrent Pharmaceuticals management said on order book — free account, 30 seconds.

Capex plans

Yes
  • No specific new capex or expansion of MR (Medical Representative) force planned currently; about 1000 MRs added over last 12-18 months covering regional expansion (Page 15).
  • Focus on operational efficiencies and integration benefits from Curatio acquisition; further margin improvements expected due to operating leverage (Pages 12, 15).
  • New product launches planned: 6 in Brazil for the year, with rep expansions to support these (Page 9).
  • Expansion in pediatric and dermatology segments through increased coverage and calls (Page 9).
  • Bileshwarpura plant has started commercial production; expected to launch 2-3 products annually going forward (Page 5).
  • Pipeline includes about 10 Onco assets planned for launch over next 4 years, with high single-digit new filing rate for the US (Page 6).
  • No major inorganic growth planned outside Indian branded businesses; Curatio acquisition cited as preferred inorganic route (Page 7).
  • Consumer health: 3-4 new products by year-end, about 5 next year; fixed costs mostly absorbed; limited incremental advertising expenses (Page 4).

Track Torrent Pharmaceuticals — get its next earnings analysis in your feed

How does Torrent Pharmaceuticals rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisTorrent Pharmaceuticals
Rev 3Mar 3

How does Torrent Pharmaceuticals rank in Pharmaceuticals & Biotechnology?

Compare Torrent Pharmaceuticals against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →